Clinical trial

Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

NCT05473741

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2023-01-11

PhaseN/A

Study timeline

Study start (actual)2023-01-11Date precision: day

Registry last updated2026-04-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Schizophreniaunresolved

Schizophrenia Relapseunresolved

Interventions

Second Generation Long-Acting Injectable Antipsychotic MedicationsDRUG

Sponsors & collaborators

Centre for Addiction and Mental Healthlead sponsor

Janssen Inc.collaborator

Mapped research locations

TorontoOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05473741 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.